Clinical Nutrition For Chronic Kidney Diseases Market

Clinical Nutrition For Chronic Kidney Diseases Market - Recent Industry Developments and Growth Strategies till 2030

نشر بتاريخ 2025-09-03 06:06:13

The global clinical nutrition for chronic kidney diseases market size was valued at USD 1.57 billion in 2023 and is projected to reach USD 2.37 billion by 2030, expanding at a CAGR of 6.03% from 2024 to 2030. The growth of this market is primarily driven by the increasing demand for specialized clinical nutrition among individuals diagnosed with CKD. Chronic kidney disease has emerged as a major global health burden, especially in low and middle-income countries that often lack adequate healthcare infrastructure to manage its long-term effects. CKD is now one of the leading causes of death worldwide and remains one of the few non-communicable diseases (NCDs) that has recorded a steady rise in related mortality rates over the past two decades. The large patient pool, coupled with the serious consequences of the disease including progression to kidney failure and increased cardiovascular risks has reinforced the need for enhanced nutrition-based interventions, better prevention strategies, and improved treatment protocols.

Although the market growth is considered moderate in pace, the demand trajectory shows signs of acceleration due to rising awareness of the role of nutritional therapy in CKD management. The clinical nutrition for CKD market is relatively concentrated and features a moderate level of innovation. Increasing research efforts in the fields of natural compounds and nutraceuticals have significantly broadened the growth opportunities. Medical foods enriched with bioactive ingredients such as polyunsaturated fatty acids, phytosterols, and phenolic compounds are gaining traction. According to a 2021 NCBI study, plant-derived compounds like resveratrol and curcumin have shown promising benefits by reducing oxidative stress and slowing CKD progression, thereby mitigating cardiovascular complications. Such findings highlight the potential for expanding the product portfolio beyond traditional formulations. For example, in 2021, Vitaflo International Ltd. was actively researching its product Renastart, which helps maintain nutritional balance in children suffering from CKD—an innovation that reflects the growing focus on patient-specific solutions.

Key Market Trends & Insights:

North America dominated the market in 2023, accounting for over 30% of the revenue share, primarily due to high disease prevalence, advanced healthcare infrastructure, and greater adoption of clinical nutrition interventions.
Asia Pacific is anticipated to grow at the fastest CAGR of nearly 7% from 2024 to 2030, driven by a rising CKD patient base, growing healthcare investments, and increased awareness about nutritional management.
By product, oral clinical nutrition dominated the market in 2023, holding over 50% share, owing to its ease of administration and patient compliance. However, parenteral feeding formulas are projected to record the fastest growth during the forecast period, particularly for patients in advanced CKD stages who have difficulties with oral intake.
By stage, adults contributed to over 85% of the revenue share in 2023, reflecting the higher prevalence of CKD in the adult population. This segment is also expected to register the fastest growth due to the increasing aging population globally.
By sales channel, the institutional sales segment dominated the market with over 40% share in 2023, supported by hospital and clinic-based recommendations. Meanwhile, the online sales segment is projected to experience the fastest growth, driven by the rising adoption of e-commerce platforms and digital healthcare services.

Order a free sample PDF of the Clinical Nutrition For Chronic Kidney Diseases Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

2023 Market Size: USD 1.57 Billion
2030 Projected Market Size: USD 2.37 Billion
CAGR (2024-2030): 6.03%
North America: Largest market in 2023
Asia Pacific: Fastest growing market

Key Companies & Market Share Insights:

The global CKD clinical nutrition market is highly consolidated, with major international players holding a significant share. Companies are actively collaborating with regional players to strengthen distribution networks and broaden their global presence. Prominent players in this space include Abbott Nutrition, Nestlé Health Science S.A., Danone Nutricia, Fresenius Kabi AG, and Mead Johnson & Company, LLC.

To ensure long-term competitiveness, these companies are pursuing diverse strategies, including product innovations, mergers and acquisitions, regional expansions, and strategic collaborations. For instance, global leaders are increasingly partnering with local distributors and leveraging regional sales channels to extend their reach to underserved markets. This approach not only supports business expansion but also enhances access to specialized nutrition for CKD patients worldwide.

Key Players

Abbott Nutrition
Pfizer Inc.
Bayer AG
Nestle Health Science S.A.
GlaxoSmithKline plc
Baxter International Inc.
Otsuka Holdings Co., Ltd.
Mead Johnson & Company, LLC
Danone Nutricia
Victus, Inc.

Explore our latest blogs: Global Industry Herald

Conclusion:

In conclusion, the global clinical nutrition for chronic kidney diseases market is set to grow steadily, driven by the increasing prevalence of CKD and the rising need for effective nutritional interventions. Growing research into natural compounds, nutraceuticals, and specialized formulations is expanding the scope of treatment and prevention, particularly as oxidative stress management and cardiovascular protection gain importance. While North America continues to lead the market, Asia Pacific presents the fastest-growing opportunities due to its large patient base and improving healthcare infrastructure. With leading players investing in innovation, collaborations, and regional expansion, the market is positioned to play a vital role in enhancing patient outcomes and addressing the global burden of CKD.